Boston Scientific Corporation, trading on the NYSE under the symbol BSX, is a leader in medical technology. The company is known for its innovative solutions that improve patient health worldwide. It offers a range of high-performance products for complex diseases across various medical fields. Boston Scientific competes with other major players in the medical technology industry, such as Medtronic and Johnson & Johnson.
Boston Scientific is set to participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Key executives, including Dan Brennan, Art Butcher, and Dr. Kenneth Stein, will engage in a 30-minute fireside chat. This session will be available via a live webcast, with a replay accessible shortly after the event. This participation highlights the company's commitment to engaging with investors and stakeholders.
On February 19, 2025, Dan Brennan, the Executive Vice President and CFO, sold 67,333 shares of Boston Scientific stock at approximately $105.24 each. After this transaction, he still holds 225,808 shares. This sale is part of routine financial management and does not necessarily indicate a lack of confidence in the company's future.
Currently, BSX stock is priced at $104.86, reflecting a decrease of 0.81, or -0.77%. The stock has fluctuated between $104.35 and $105.46 today. Over the past year, BSX has seen a high of $107.17 and a low of $65.52. The company's market capitalization is approximately $154.5 billion, indicating its significant presence in the market.
Today's trading volume for BSX is 2,217,759 shares, showing active investor interest. The stock's performance and trading activity are important indicators for investors. As Boston Scientific continues to innovate and expand its offerings, its participation in industry events like the TD Cowen conference is crucial for maintaining investor confidence and market presence.
